Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid

W. A. Keitel, K. E. Kester, R. L. Atmar, A. C. White, N. H. Bond, C. A. Holland, U. Krzych, D. R. Palmer, A. Egan, C. Diggs, W. R. Ballou, B. F. Hall, D. Kaslow

Research output: Contribution to journalArticle

72 Scopus citations

Abstract

The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)531-539
Number of pages9
JournalVaccine
Volume18
Issue number5-6
DOIs
StatePublished - Oct 14 1999
Externally publishedYes

Keywords

  • Malaria vaccines
  • Merozoite surface protein
  • Plasmodium falciparum

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1<sub>19</sub>) and T helper epitopes of tetanus toxoid'. Together they form a unique fingerprint.

  • Cite this

    Keitel, W. A., Kester, K. E., Atmar, R. L., White, A. C., Bond, N. H., Holland, C. A., Krzych, U., Palmer, D. R., Egan, A., Diggs, C., Ballou, W. R., Hall, B. F., & Kaslow, D. (1999). Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid. Vaccine, 18(5-6), 531-539. https://doi.org/10.1016/S0264-410X(99)00221-2